Compound Index

Tracking 9 GLP-1 and peptide therapeutics across clinical development stages.

LY3298176

Tirzepatide

Approved
TargetGLP-1 / GIP
Primary IndicationT2D / Obesity
DeveloperEli Lilly
NN9535

Semaglutide

Approved
TargetGLP-1
Primary IndicationT2D / Weight Mgmt
DeveloperNovo Nordisk
NN2211

Liraglutide

Approved
TargetGLP-1
Primary IndicationT2D / Weight Mgmt
DeveloperNovo Nordisk
LY3437943

Retatrutide

Phase III
TargetGLP-1 / GIP / Glucagon
Primary IndicationObesity / MAFLD
DeveloperEli Lilly
LY3502970

Orforglipron

Phase III
TargetGLP-1
Primary IndicationT2D / Obesity (Oral)
DeveloperEli Lilly
NN9459

Cagrilintide

Phase III
TargetAmylin
Primary IndicationObesity
DeveloperNovo Nordisk
BI 456906

Survodutide

Phase II
TargetGLP-1 / Glucagon
Primary IndicationNASH / Obesity
DeveloperBoehringer Ingelheim
VK2735

VK2735

Phase II
TargetGLP-1 / GIP
Primary IndicationObesity
DeveloperViking Therapeutics
AMG 133

MariTide

Phase II
TargetGLP-1 / GIP
Primary IndicationObesity / Osteoarthritis
DeveloperAmgen